Overview
The Best of Targeted Therapies of Lung Cancer (TTLC) 2026 Webinar is designed to bring the data on relevant targets for new therapies to the researchers and healthcare professionals who treat patients with thoracic malignancies, and to ensure their understanding of the data on preclinical and early clinical trials for each of the drugs directed against relevant targets.
- Analyze recent clinical trial data and emerging treatment strategies in targeted therapies for lung cancer presented at TTLC and apply key findings to treatment decision-making for patients.
- Summarize important updates in immunotherapy for lung cancer from TTLC, including novel agents, combination approaches, and evolving clinical evidence relevant to patient management.
- Evaluate current advances and emerging therapeutic strategies in small cell lung cancer presented at TTLC and assess their potential implications for clinical practice.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME). The International Association for the Study of Lung Cancer is accredited by the ACCME to provide continuing medical education for physicians.
The International Association for the Study of Lung Cancer designates the live format for this educational activity for a maximum of 1.00 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
- Analyze recent clinical trial data and emerging treatment strategies in targeted therapies for lung cancer presented at TTLC and apply key findings to treatment decision-making for patients.
- Summarize important updates in immunotherapy for lung cancer from TTLC, including novel agents, combination approaches, and evolving clinical evidence relevant to patient management.
- Evaluate current advances and emerging therapeutic strategies in small cell lung cancer presented at TTLC and assess their potential implications for clinical practice.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME). The International Association for the Study of Lung Cancer is accredited by the ACCME to provide continuing medical education for physicians.
The International Association for the Study of Lung Cancer designates the live format for this educational activity for a maximum of 1.00 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Share
Participants
Deborah Doroshow
MD, PhD
Assistant Professor of Medicine
Icahn School of Medicine at Mount Sinai, New York City, New York, USA
Luis Raez
MD, FACP, FCCP
Medical Director, Chief Scientific Officer
Memorial Cancer Institute (MCI)
Oncology Research Director of Memorial Health Care System (MHS)
Paul Bunn
MD
Distinguished Professor, Medicine-Medical Oncology
University of Colorado Anschutz
Former Chief Executive Officer of IASLC
Former President of ASCO
Melinda Hsu
MD
Assistant Professor
CWRU School of Medicine; Ohio, USA
Ticiana Leal
MD
Director, Thoracic Medical Oncology Program, Department of Hematology and Medical Oncology
Emory School of Medicine; Georgia, USA